Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine
- 31 December 1999
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 93 (3) , 232-238
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cytokine‐inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor κB and signal transducer and activato of transcription‐1FEBS Letters, 1999
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptideMultiple Sclerosis Journal, 1998
- CD40-CD40L interactions inatherosclerosisImmunology Today, 1997
- CD40 and Its Ligand in AutoimmimityAnnals of the New York Academy of Sciences, 1997
- CD40 engagement induces monocyte procoagulant activity through an interleukin‐10 resistant pathwayEuropean Journal of Immunology, 1996
- Proliferating dendritic cell progenitors in human blood.Journal of Experimental Medicine, 1994
- Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40Science, 1993
- Decrease of platelet aggregation and spreading via inhibition of the cAMP phosphodiesterase by trapidilFEBS Letters, 1984
- A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factorLife Sciences, 1981